AxoGen(NASDAQ:AXGN) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Feb 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $11.409M. Analysts estimated a revenue of $10.970M. The revenues were 4% above the estimates. Earnings per share were $-0.1. The reported EPS was below estimates by -11.11%. Analysts had estimated an EPS of $-0.09.
AxoGen (AXGN) shares turned negative on Wednesdays trading session with the shares closing down -0.1 points or -0.94% at a volume of 1,14,401. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $10.649. The peak price level was also seen at $10.649 while the days lowest was $10.25. Finally the shares closed at $10.5. The 52-week high of the shares is $11.249 while the 52-week low is $4.87. According to the latest information available, the market cap of the company is $345 M.
Several Insider Transactions has been reported to the SEC. On Oct 14, 2016, Amy Mcbride Wendell (director) purchased 13,333 shares at $7.50 per share price.Also, On Oct 14, 2016, Peter J Mariani (CFO) purchased 3,333 shares at $7.50 per share price.On Oct 14, 2016, Kevin Leach (Vice President Marketing) purchased 2,000 shares at $7.50 per share price, according to the Form-4 filing with the securities and exchange commission.